Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

8 results
3:13 PM, Oct 06, 2017  |  BioCentury | Finance

CRISPRing out new targets

led by Flagship. Also participating were fellow founding investor Polaris Partners, Arch Venture Partners and Alexandria Equities
12:00 AM, Sep 14, 2015  |  BioCentury | Finance

Periodic piece

in July 2014 with Arch, Polaris Partners, Osage University Partners, the Washington Research Foundation and Alexandria Equities
12:00 AM, Sep 08, 2014  |  BioCentury | Emerging Company Profile

Flex: Flexing muscle

Funds raised: $38 million Investors: Longwood Fund LP, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, Alexandria Equities
12:00 AM, Apr 16, 2007  |  BioCentury | Emerging Company Profile

Corporate Profile

raised: $34 million Investors: Arch Venture Partners; Canaan Partners; Healthcare Ventures; MPM Capital; Amgen Ventures; Alexandria Equities
12:00 AM, Feb 26, 2007  |  BioCentury | Finance

Ebb & Flow

that will include ARCH; Venrock Associates; 5AM; Altitude Life Science Ventures; Washington Research Foundation; and Alexandria Equities
12:00 AM, Apr 05, 2004  |  BioCentury | Finance

Ebb & Flow

investors included OrbiMed; Easton Hunt; Hunt Ventures; Novo A/S; Quilvest Capital; Clariden Bank; InterWest; Versant; Alexandria Equities
12:00 AM, Jun 24, 2002  |  BioCentury | Emerging Company Profile

Corporate Profile

Associates, Advent Venture Partners, HBM Bioventure, Vulcan Ventures, Novartis Bioventures, Wellcome Trust, Tallwood, Lotus Biosciences, Alexandria Equities
12:00 AM, Jun 24, 2002  |  BioCentury | Finance

Ebb & Flow

Global Investments; GeneChem Therapeutics Venture Fund; ProQuest Investments; Ventures West; InterWest Partners; Versant Ventures; and Alexandria Equities
Partners; Vulcan Ventures; HBM BioVentures; Novartis BioVenture Fund; Wellcome Trust; Tallwood Venture Capital; Lotus BioScience; Alexandria Equities